Connect with us

Technology

Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer

Published

on

VALBY, Denmark, May 6, 2025 /PRNewswire/ — H. Lundbeck A/S is pleased to announce its agreement with the Danish Centre for AI Innovation (DCAI), the company established to run and operate Gefion, Denmark’s flagship AI supercomputer. Lundbeck is one of the first pharmaceutical companies to leverage Gefion to accelerate drug discovery and development in neurological and psychiatric disorders.

Brain disorders are estimated to affect half the world’s population, significantly impairing quality of life. Despite scientific advancements, there are still high unmet needs within brain health, and many patients have limited options for treatment. By leveraging Gefion’s unparalleled AI computational power, Lundbeck aims to enhance and expedite the discovery of next-generation treatments. 

Lundbeck expects that Gefion will contribute to advancing research by providing AI-driven insights into molecule discovery and drug optimization in the development of therapies. By exploring innovative avenues for molecule discovery, Lundbeck aims to identify novel and better medicines for known drug targets as well as unlocking emerging drug targets to deliver new treatment options for people living with brain disorders, including rare and specialist-treated neurological conditions. 

Senior Vice President & Head of Research at Lundbeck, Tarek Samad, emphasizes the significance of AI-driven innovation and drug discovery in Lundbeck’s Focused Innovator strategy: “We are excited to be among the pioneers utilizing Gefion’s AI supercomputing power. The advanced computational capabilities of Gefion come with the promise of potentially allowing us to push the boundaries of tackling brain diseases and develop treatments at an unprecedented pace.” 

“It’s an exciting milestone for us to work with such a big customer and innovator in the pharmaceutical space like Lundbeck,” says Nadia Carlsten, CEO of the Danish Centre for AI Innovation (DCAI). “We’ve been maturing Gefion since its launch just a few months ago, and to see its computing power now helping Lundbeck’s scientists uncover new treatment pathways more efficiently is very rewarding. This agreement has the potential to accelerate the timeline for bringing impactful neurological therapies to patients.”

Advancing neuroscience with AI-powered research 

Senior Vice President of Global IT at Lundbeck, Claus Thomsen, highlights the key role of AI in Lundbeck’s IT strategy: “Working together with DCAI marks an important step towards transforming brain disease research by employing AI. Providing our researchers with access to Gefion and the state-of-the-art software stack opens the opportunity to leverage the fast-evolving development of AI-driven analysis and large-scale simulations. This supports our strategy to harness the power of AI for the benefit of our patients.” 

The agreement between DCAI and Lundbeck is a significant milestone in relation to applying Gefion’s potential in pharmaceutical research and development. Other companies are already employing Gefion for projects spanning foundational AI research, human-centric healthcare solutions, and pharmaceutical and biotech innovation, as well as initiatives within other industries. 

“As AI reshapes industries, Gefion stands at the forefront of revolutionizing research and innovation. Together with Lundbeck we can demonstrate the game-changing potential of AI supercomputing in tackling some of the world’s most urgent healthcare challenges,” says Nadia Carlsten, CEO of the Danish Centre for AI Innovation (DCAI). 

Contacts
Marie Petterson
Head of Media Relations, Corp. Communication
MEEP@lundbeck.com
+45 29 82 21 82

Danish Centre for AI Innovation
hello@dcai.dk

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world’s population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has approximately 5,500 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

About DCAI

The Danish Centre for AI Innovation (DCAI) owns and operates Gefion, Denmark’s flagship AI supercomputer, designed specifically for large-scale AI projects. Gefion ranks among the most powerful supercomputers globally powered by 1.528 NVIDIA H100 Tensor Core GPUs. DCAI’s mission is to lower the barrier for accessing advanced computing capabilities, enabling customers to innovate and fostering ecosystem growth. DCAI customers include academic researchers, startups, government institutions, and enterprise customers doing large scale innovation. DCAI was formed as a company and funded by the Novo Nordisk Foundation and EIFO in 2024.

CONTACT: 
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
+45 3630 1311
info@lundbeck.com

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/h–lundbeck-a-s/r/lundbeck-joins-forces-with-danish-centre-for-ai-innovation-to-improve-brain-health-by-advancing-drug,c4144045

The following files are available for download:

 

View original content:https://www.prnewswire.com/news-releases/lundbeck-joins-forces-with-danish-centre-for-ai-innovation-to-improve-brain-health-by-advancing-drug-discovery-with-gefion-ai-supercomputer-302446892.html

SOURCE H. Lundbeck A/S

Continue Reading

Technology

BCE reports results of Series S and T preferred share conversions

Published

on

By

MONTRÉAL, Oct. 19, 2026 /CNW/ — BCE Inc. (TSX: BCE) (NYSE: BCE) today announced that 400 of its 4,798,333 fixed-rate Cumulative Redeemable First Preferred Shares, Series T (“Series T Preferred Shares”) have been tendered for conversion on November 2, 2026, on a one-for-one basis, into floating-rate Cumulative Redeemable First Preferred Shares, Series S (“Series S Preferred Shares”). In addition, 676,765 of its 1,866,877 Series S Preferred Shares have been tendered for conversion on November 2, 2026, on a one-for-one basis, into Series T Preferred Shares. Consequently, on November 2, 2026, BCE will have 5,474,698 Series T Preferred Shares and 1,190,512 Series S Preferred Shares issued and outstanding. The Series T Preferred Shares and the Series S Preferred Shares will continue to be listed on the Toronto Stock Exchange under the symbols BCE.PR.T and BCE.PR.S, respectively.

The Series T Preferred Shares will pay on a quarterly basis, for the five-year period beginning on November 2, 2026, as and when declared by the Board of Directors of BCE, a fixed cash dividend based on an annual fixed dividend rate of 5.523%.

The Series S Preferred Shares will continue to pay a monthly floating adjustable cash dividend for the five-year period beginning on November 2, 2026, as and when declared by the Board of Directors of BCE. The monthly floating adjustable dividend for any particular month will continue to be calculated based on the prime rate for such month and using the Designated Percentage for such month representing the sum of an adjustment factor (based on the market price of the Series S Preferred Shares in the preceding month) and the Designated Percentage for the preceding month.

About BCE
BCE is Canada’s largest communications company1, leading the way in advanced fibre and wireless networks, enterprise services and digital media. By delivering next-generation technology that leverages cloud-based and AI-driven solutions, we’re keeping customers connected, informed and entertained while enabling businesses to compete on the world stage. To learn more, please visit Bell.ca or BCE.ca.

1 Based on total revenue and total combined customer connections.

Media inquiries:
Ellen Murphy
media@bell.ca

Investor inquiries:
Krishna Somers
krishna.somers@bell.ca

View original content:https://www.prnewswire.com/news-releases/bce-reports-results-of-series-s-and-t-preferred-share-conversions-302913268.html

SOURCE BCE Inc.

Continue Reading

Technology

3M announces collaboration with GSEO to advance Expanded Beam Optical manufacturing and development

Published

on

By

ST. PAUL, Minn., Oct. 19, 2026 /PRNewswire/ — 3M (NYSE: MMM) today announced a collaboration with Genius Electronic Optical Co., Ltd. (GSEO, Taiwan: 3406), an optical technology company, to advance technology development and manufacturing for 3M’s Expanded Beam Optical (EBO) solutions. In support of these efforts, 3M expects to make a strategic investment to acquire approximately 4.7% of GSEO’s common shares as part of the company’s private placement of newly issued shares, subject to customary closing conditions.

The collaboration brings together 3M’s EBO technology leadership, optical interconnect expertise, materials science, manufacturing scale and customer relationships with GSEO’s precision optics manufacturing capabilities and production scale. Together, the companies aim to support EBO commercialization and long-term capacity expansion to meet growing demand from hyperscale data centers and other advanced connectivity applications.

“3M is investing in capabilities and partnerships that can accelerate innovation for our customers,” said William Brown, 3M Chairman and CEO. “By selecting GSEO as a manufacturing partner and investing in the company, we are strengthening the path to scale next-generation optical connectivity solutions for high-performance data center infrastructure.”

GSEO’s existing precision optics manufacturing capabilities and technical development experience are expected to support manufacturing readiness for 3M’s EBO ferrules, co-packaged optics solutions and related optical interconnect applications. The collaboration is part of 3M’s broader EBO ecosystem strategy, which includes continued work with customers and partners across the optical interconnect market.

“GSEO is pleased to expand its relationship with 3M as we work together to advance optical interconnect solutions for next-generation data center infrastructure,” said Micro Kuo, GSEO CEO and President. “This collaboration brings together complementary technology and manufacturing strengths to support continued innovation and help meet the performance demands of high-growth connectivity markets.”

3M expects the strategic investment to close in the fourth quarter of 2026, subject to customary closing conditions.

Forward-Looking Statements
Certain statements in this release are considered “forward-looking statements” under the federal securities laws, including the Private Securities Litigation Reform Act of 1995, as amended, and are intended to enjoy the protection of those laws. Forward-looking statements may appear throughout this release and are typically identified by the words “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “evaluate,” “expect,” “forecast,” “future,” “goal,” “guidance,” “impact,” “initial,” “intend,” “likely,” “may,” “outlook,” “plan,” “possible,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would,” and other words that are similar to, or have the opposite meanings of, those words. Forward-looking statements speak only as of the date they are made, 3M assumes no duty to update those statements, and readers are cautioned not to place undue reliance on any of those statements. Forward-looking statements are based on certain assumptions and expectations of future events and trends that are subject to risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” of 3M’s Form 10-K for the year ended December 31, 2025.

About 3M
3M (NYSE: MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global footprint, and operational excellence. Discover how 3M is shaping the future at 3M.com/news.

Contacts
3M
Investor Contact:
Diane Farrow, 612-202-2449
Media Contact:
3MNews@mmm.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/3m-announces-collaboration-with-gseo-to-advance-expanded-beam-optical-manufacturing-and-development-302913170.html

SOURCE 3M Company

Continue Reading

Technology

Scott Vicknair Personal Injury Lawyers Announces Second Annual Operation Fur-Ever Home Pet Adoption Event at Lafreniere Park

Published

on

By

NEW ORLEANS, Oct. 19, 2026 /PRNewswire/ — Scott Vicknair Personal Injury Lawyers is excited to announce the return of its second annual Operation Fur-Ever Home, a free community pet adoption event taking place on Saturday, November 14, 2026, from 9:00 a.m. to 11:00 a.m. at Lafreniere Park in Metairie, Louisiana.

The free, family-friendly event will give attendees the opportunity to meet adoptable pets from local animal shelters, learn about responsible pet ownership, and potentially welcome a new furry companion into their homes. Those who preregister for the event will also be entered for a chance to win a Soundcore speaker and a free pet adoption.

“Last year’s event was everything we hoped it would be, and we are incredibly excited to bring Operation Fur-Ever Home back for a second year,” said David Vicknair, founding partner of Scott Vicknair Personal Injury Lawyers. “There is something special about watching a family meet a pet that could become part of their lives for years to come. We wanted to create another opportunity to make those connections while supporting the organizations that work tirelessly to care for animals in our community.”

Building on the success of the first event, this year’s event continues the firm’s commitment to supporting local animal shelters and creating meaningful opportunities for families throughout Southeast Louisiana.

“Giving back to our community has always been an important part of who we are as a firm,” said Vicknair. “Whether we are helping students prepare for school, recognizing deserving teachers, or supporting local animal shelters, our goal is to make a positive difference in the communities we serve.”

Operation Fur-Ever Home is free and open to the public. Families, animal lovers, and anyone interested in adopting a pet are encouraged to attend and preregister.

About Scott Vicknair Personal Injury Lawyers

Scott Vicknair Personal Injury Lawyers is a New Orleans-based personal injury firm committed to providing exceptional legal representation while also investing in the communities it serves. Their experienced team of dedicated attorneys specializes in car accidents, personal injury, and wrongful death cases in New Orleans. With diverse personal and professional backgrounds, they craft legal strategies tailored to each client’s specific case and needs.

View original content:https://www.prnewswire.com/news-releases/scott-vicknair-personal-injury-lawyers-announces-second-annual-operation-fur-ever-home-pet-adoption-event-at-lafreniere-park-302913183.html

SOURCE Scott Vicknair Personal Injury Lawyers

Continue Reading

Trending